These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 24777594)

  • 1. Subcutaneous trastuzumab: drug development and current position.
    Martín Martorell P; Bermejo de Las Heras B; Pérez-Fidalgo JA; Huerta Alvaro M; Martín M; Albanell J; Lluch Hernández A
    Clin Transl Oncol; 2014 Oct; 16(10):859-64. PubMed ID: 24777594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of subcutaneous formulation of trastuzumab in the treatment of patients with HER2-positive breast cancer.
    Melichar B; Študentová H; Kalábová H; Vitásková D
    Immunotherapy; 2014; 6(7):811-9. PubMed ID: 25290414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study.
    Tan AR; Im SA; Mattar A; Colomer R; Stroyakovskii D; Nowecki Z; De Laurentiis M; Pierga JY; Jung KH; Schem C; Hogea A; Badovinac Crnjevic T; Heeson S; Shivhare M; Kirschbrown WP; Restuccia E; Jackisch C;
    Lancet Oncol; 2021 Jan; 22(1):85-97. PubMed ID: 33357420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An appraisal of subcutaneous trastuzumab: a new formulation meeting clinical needs.
    Launay-Vacher V
    Cancer Chemother Pharmacol; 2013 Dec; 72(6):1361-7. PubMed ID: 24057040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic review of dual targeting in HER2-positive breast cancer.
    Kümler I; Tuxen MK; Nielsen DL
    Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies.
    Pinto AC; Ades F; de Azambuja E; Piccart-Gebhart M
    Breast; 2013 Aug; 22 Suppl 2():S152-5. PubMed ID: 24074778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal sequencing of anti-HER2 therapy throughout the continuum of HER2-positive breast cancer: evidence and clinical considerations.
    Harbeck N; Wuerstlein R
    Drugs; 2013 Oct; 73(15):1665-80. PubMed ID: 24127221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subcutaneous Trastuzumab Combined with Pertuzumab and Docetaxel as First-line Treatment of Advanced HER2-positive Breast Cancer.
    Stefanou D; Kokkali S; Tripodaki ES; Drizou M; Magou E; Zylis D; Prevezanou M; Kapiris M; Nasi D; Ntokou A; Dede M; Ardavanis A
    Anticancer Res; 2018 Nov; 38(11):6565-6569. PubMed ID: 30396987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study.
    Pivot X; Gligorov J; Müller V; Barrett-Lee P; Verma S; Knoop A; Curigliano G; Semiglazov V; López-Vivanco G; Jenkins V; Scotto N; Osborne S; Fallowfield L;
    Lancet Oncol; 2013 Sep; 14(10):962-70. PubMed ID: 23965225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trastuzumab and beyond: New possibilities for the treatment of HER2-positive breast cancer.
    Morris SR; Carey LA
    Oncology (Williston Park); 2006 Dec; 20(14):1763-71; discussion 1771-2, 1774-6. PubMed ID: 17263127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of subcutaneous and intravenous administration of trastuzumab: a phase I/Ib trial in healthy male volunteers and patients with HER2-positive breast cancer.
    Wynne C; Harvey V; Schwabe C; Waaka D; McIntyre C; Bittner B
    J Clin Pharmacol; 2013 Feb; 53(2):192-201. PubMed ID: 23436264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a Subcutaneous Fixed-Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose-Finding Study.
    Kirschbrown WP; Wynne C; Kågedal M; Wada R; Li H; Wang B; Nijem I; Badovinac Crnjevic T; Gasser H; Heeson S; Eng-Wong J; Garg A
    J Clin Pharmacol; 2019 May; 59(5):702-716. PubMed ID: 30570763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pertuzumab for the treatment of patients with previously untreated HER2-positive metastatic breast cancer.
    Smith MB; Reardon J; Olson EM
    Drugs Today (Barc); 2012 Nov; 48(11):713-22. PubMed ID: 23170307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subcutaneous trastuzumab (Herceptin). Ready to use, but more serious adverse effects than intravenous (IV) trastuzumab.
    Prescrire Int; 2015 Apr; 24(159):93. PubMed ID: 25941697
    [No Abstract]   [Full Text] [Related]  

  • 15. Current Progress in Human Epidermal Growth Factor Receptor 2 Targeted Therapies in Esophagogastric Cancer.
    Janjigian YY; Braghiroli MI
    Surg Oncol Clin N Am; 2017 Apr; 26(2):313-324. PubMed ID: 28279471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trastuzumab: a review of its use in the management of HER2-positive metastatic and early-stage breast cancer.
    Plosker GL; Keam SJ
    Drugs; 2006; 66(4):449-75. PubMed ID: 16597163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of trastuzumab in the management of HER2-positive metastatic breast cancer: an updated review.
    Tokuda Y; Suzuki Y; Saito Y; Umemura S
    Breast Cancer; 2009; 16(4):295-300. PubMed ID: 19609647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subcutaneous Trastuzumab: A Review in HER2-Positive Breast Cancer.
    Heo YA; Syed YY
    Target Oncol; 2019 Dec; 14(6):749-758. PubMed ID: 31686307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subcutaneous trastuzumab: a review of its use in HER2-positive breast cancer.
    Sanford M
    Target Oncol; 2014 Mar; 9(1):85-94. PubMed ID: 24664187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long term survival of HER2-positive early breast cancer treated with trastuzumab-based adjuvant regimen: a large cohort study from clinical practice.
    Bonifazi M; Franchi M; Rossi M; Zambelli A; Moja L; Zambon A; Corrao G; La Vecchia C; Zocchetti C; Negri E
    Breast; 2014 Oct; 23(5):573-8. PubMed ID: 24934637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.